Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...
November 2025
Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment
Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative...
DualityBio Secures FDA Fast‑Track Designation for EGFR/HER3 Bispecific ADC AVZO‑1418
Duality Biotherapeutics, Inc. (DualityBio, HKG: 9606) announced that its co‑developed EGFR/HER3 bispecific antibody‑drug conjugate (ADC),...
Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform
Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology...
Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) reported that both pivotal Phase III trials of its...
Simcere Launches Phase II Trial of T‑Reg‑Selective IL‑2 Fusion (SIM0278) for Moderate‑to‑Severe Atopic Dermatitis in China
Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase II clinical study of its proprietary...
Gaush Meditech’s Subsidiary Secures China Registration for Integrated Ophthalmic Electrophysiology System
Gaush Meditech Ltd. (HKG: 2407) announced that its wholly‑owned subsidiary Gaush Tech Ltd. has been issued...
Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005
Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of...
Mabwell’s 9MW3811 Gains NMPA Approval to Launch World‑First IL‑11‑Targeting Phase 2 Trial for Pathological Scarring
Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from...
MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4
MeiraGTx Holdings plc (NASDAQ: MGTX) announced a strategic ophthalmology collaboration with Eli Lilly and Company...
Innovent Biologics & Sanegene Bio USA Report First‑in‑Human Success for IBI3016 siRNA Hypertension Therapy
Innovent Biologics, Inc. (HKG: 1801) and Sanegene Bio USA Inc. announced today the first‑in‑human (FIH)...
Hangzhou Bio‑Sincerity Secures NMPA Approval for BIOS‑0625 Tablet – First‑in‑Class Ulcerative Colitis Therapy
Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...
CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines
CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...
Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China
Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...
Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial
Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...
Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance
Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...
DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform
Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...
Organon Acquires JADA System from Laborie for USD 465 Million
Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...
HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...